Treatment with decitabine induces the expression of stemness markers, PD-L1 and NY-ESO-1 in colorectal cancer: potential for combined chemoimmunotherapy

Abstract Background The mechanism of tumor immune escape and progression in colorectal cancer (CRC) is widely investigated in-vitro to help understand and identify agents that might play a crucial role in response to treatment and improve the overall survival of CRC patients. Several mechanisms of i...

Full description

Bibliographic Details

Published in:	Journal of Translational Medicine
Main Authors:	Nassiba Taib, Maysaloun Merhi, Varghese Inchakalody, Sarra Mestiri, Shereena Hydrose, Karama Makni-Maalej, Afsheen Raza, Fairooz Sahir, Fouad Azizi, Parveen B. Nizamuddin, Queenie Fernandes, Zeenath Safira K. M. Yoosuf, Salam Almoghrabi, Lobna Al-Zaidan, Alaaeldin Shablak, Shahab Uddin, Cristina Maccalli, Mohammed Ussama Al Homsi, Said Dermime
Format:	Article
Language:	English
Published:	BMC 2023-03-01
Subjects:	Colorectal cancer Decitabine NY-ESO-1 PD-L1 Stemness markers Chemoresistance
Online Access:	https://doi.org/10.1186/s12967-023-04073-y